The Phase 3 clinical development program for ZerenexTM (ferric citrate) for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease on dialysis was conducted under a Special Protocol Assessment (SPA) agreement with the FDA and was completed in January 2013.
In November 2012, the Company initiated a Phase 2 clinical study of ZerenexTM for the Treatment of Patients with Non-Dialysis Dependent Chronic Kidney Disease. For more information on this Phase 2 study, which is currently ongoing, please click HERE to be directed to the listing at clinicaltrials.gov.
Disclaimer: This investigational drug product has not been approved by the US Food and Drug Administration for safety and effectiveness. This investigational drug product is still undergoing clinical study to verify its safety and effectiveness